ANTIMICROBIAL RESISTANCE SOLUTIONS
WITH DR. JOHN H. REX
Latest Newsletters
Latest Government Action





















R&D Insight
Can you help?
Antimicrobial resistance poses a catastrophic threat. If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics. And routine operations like hip replacements or organ transplants could be deadly because of the risk of infection.
Dame Sally Davies Tweet


















FDA and EMA regulatory updates / Fireside chat during the 4th AMR Conference
Assessing antibiotic value: DTR, fire extinguishers, and a view from Australia
Developing antibiotics for children: There are no easy answers
Impact of PASTEUR: 9.9m lives saved, ROI of 125:1
FDA Workshop: Animal models in support of narrow-spectrum agents for A. baumannii and P. aeruginosa
FDA Workshop: Animal Models To Support Antibacterial Development (5 Mar 2020, post-meeting notes)
Scary, Scarier, Scariest (Part 2): What can YOU do about it?
IDSA White Paper on developing narrow-spectrum antimicrobials + editorial by G. Drusano
Draft EMA antibacterial guidance: Analysis
Language matters: CRE vs. CPE; SDD vs. I; and MDR, XDR, PDR, UDR vs. DTR
News from Davos 2020: Some positive signs, but overall a fragile antibiotic market at a tipping point
Push! Pull! Push! Pull! / Highlights from Davos 2018
The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism.
Alexander Fleming Tweet

The bipartisan PASTEUR Act is the strongest bill ever written to strengthen antibiotic development and use. It will fix our market failures, expand the pipeline for next generation antibiotics, and save lives. We can’t sit on our hands as this public health crisis arrives – we have to act now.
U.S. Senator Michael Bennet Tweet